 HCC is ranked the second among all cancers in China.
Introduction
Liver cancer is one of the most aggrassive malignancies and the second cause of cancer-related death worldwide (1) (2) (3) (4) (5) . Due to metastasis at diagnosis, most patients with liver cancers are not suitable for current radiation and chemotherapy treatments (6, 7) . Molecular targerted therapy with sorafenib can improve the survival time of liver cancer patients, but drug resistance inevitably occurs at a later life time (8, 9) .
Liver resection remains the gold standard for the treatment of patients with liver cancer, but its prognosis remains very poor (10, 11) . Currently, a number of organizations including the American Association for Liver Diseases, the National Comprehensive Cancer Network of China, and the European Association for Liver Diseases published consensus guidelines for the diagnosis and treatment of liver diseases (12) (13) (14) . According to these standards, the most effective management of liver cancer patients is early diagnosis based on the known indicators of a patient (3) . Therefore, the current challenge is to develop a classifier for the early diagnosis of liver cancer by analyzing a large amount of the patient's data (15) .
Currently, alpha-fetoprotein (AFP) has been a widely used biomarker for hepatocellular carcinoma (HCC) (16) . In clinical practice, detection of alpha-fetoprotein (AFP) and abdominal ultrasound are usually applied for liver cancers diagnosis (17) (18) (19) (20) (21) (22) (23) . However, AFT has significant drawbacks for the diagnosis of HCC. First, when an abnormal AFP is detected, the vast majority of patients have already reached an advanced liver cancer stage with an extremely low cure rate.
Second, the specificity and sensitivity of AFP is low, since high levels of AFP are 5 also detected in chronic hepatitis or cirrhosis; while normal AFP levels are sometimes detected in HCC (24, 25) . In order to improve the early diagnosis of HCC, a number of candidate tumor markers including Golgi protein 73 and AFPL3 have been proposed. However, these markers have not been applied in clinic due to poor sensitivity and specificity (26) . With the advance of precision medicine, it is urgent to develop an alternative strategy for diagnosis and provide prognostic information of HCC (27) .
Furthermore, it is currently a challenge to distinguish HCC from other liver diseases such as hepatitis and cirrhosis. A rountine clinic biochemical test includes indicators of blood, urine, kidney function, liver and a series of other indicators. It is necessary for an oncologist to distinguish patients with HCC from hepatitis and cirrhosis based on these indicators (15) . However, due to the complexity of cancer, it is hard even for experienced oncologists to precisely distinguish whether a patient is suffering from HCC (28) . In order to meet this challenge, a lot of supervised learning approaches for prognosis have been developed. A decision tree analysis of cDNA microarrays has been used for non-small cell lung cancer prognosis (29) . Advanced classification algorithms have also been established to predict cancer classification.
For example, support vector machines (SVMs) have been used to select highly reliable identified genes to build a cancer classifier (30) . Nevertheless, a supervised learning method has not been used in the development of a highly predictive classifier of liver cancer (31) . In this study, based on SVM-based methods of surveillance, we successfully developed a SVM-based specific marker classifier for liver cancer by 6 integrating 22 markers. This established classifier could accurately distinguish liver cancer from other liver diseases and may provide a reference for oncologists to make effective programs in daily decision-making.
Methods

Data Sources
Liver cancer and liver disease datasets including cirrhosis and hepatitis B were 
Data Preparation
Data preprocessing was first performed by excluding irrelevant attributes such as age, gender, pathological diagnosis, coding and working unit; and including related attributes such as admission date, index, diagnosis results, results of reference, and diagnosis markers. After the removal of irrelevant attributes of patients, patients were re-indexed and abnormal indicators were filtered out due to personal reasons: severity of the disease, the patient's family's economic status, and the index of each patient was not the same. For example, some patients had more than 17 million items of measure indexes, while some patients were measured for only 30 indicators.
Moreover, a number of these indicators have repeated measurements. For an indicator, it might be tested in multiple measurements due to surgery, medication, measurement accuracy and other external factors; especially for specimens with morphology of jaundice, mild hemolysis, or mild chyle. Therefore, these inaccurate indicators were removed and a measured unified index was selected during the first patient admission.
The first detected indicators were the most significant, as they were not affected by Finally, the selected abnormal indicators were standardized as follows: above normal range was set to 2, below normal range was set to 1, and the index was set to 0 in the normal range. Data sets were imported into the SPSS Modeler for data analysis.
Procedure for the development of SVM predictive modeling
Our classifier was built in accordance to the SVM-based method. In addition, radial basis function was applied as the kernel function, because our classification problem is nonlinear (31) . Among the 1,879 samples, 382 had no tests of the above filtered 22 indicators or had less than 10 of these indicators; therefore, the SVM predictive modeling was developed based on the data set of the rest of the 1,497 HCC samples. The 1,497 samples were randomly divided into three groups: training group, testing group and validation group. The training and testing groups were used for the construction of the classifier model, while the validation group was used to predict liver cancer or liver disease using the built classifier model and to test the accuracy of 
Statistical analysis
Statistical analysis was performed on the 22 markers in the training, test and validation groups using IBM SPSS Statistic v19.0 (IBM Co., Armonk, NY, USA). The training and testing groups were analyzed as a set (Table 1) , while the validation group was analyzed as another set (Table 2) . In all analyses, a P-value <0.01 was considered statistically significant. Data are expressed as the mean ± standard deviation (SD).
Results
Correlation Analysis of Markers with Liver Cancer
Among the 1,879 patients with HCC, 1,511 were male and 371 were female. The Apriori algorithm is capable of reducing the number of sets and comparing the number of valid correlation algorithms, which is easy to implement (32) . The correlation analysis of the 63 markers of these 1,879 samples with HCC was performed using an Apriori association algorithm in the SPSS Modeler. The Apriori association algorithm was divided into two steps. In the first step, all frequent item sets were retrieved from the data source through iterations with a support threshold of 30%. In the second step, the minimum rules for confidence of 50% were constructed 10 from the retrieved frequent item sets in the first step. A total of 22 specific markers that had a strong association with liver cancer were selected based on the support of more than 39% and 100% confidence ( Table 3) .
Development of the SVM classifier
Our classifier was built in accordance to the SVM-based method using the 22 markers selected via correlation analysis. The SVM classifier model was constructed were associated with AFP, 18% were associated with γ-glutamyl transferase, 14%
were associated with absolute lymphocyte, 13% were associated with red cell distribution width, 10% were associated with alanine and aspartate, 9% were associated with RBC, 7% were associated with platelet distribution width, 3% were associated with the percentage of eosinophils, 2% were associated with hematocrit and 1% were associated with the percentage of neutrophils. The other indicators added together were related to 3% of HCCs, which is negligible ( Supplementary Table 1 and Fig. 1 ). From these data, these top 10 biomarkers were proposed as key factors for the prediction of HCC, and the remaining 12 biomarkers may serve as supplemental markers.
Diagnostic results were set as 1 for HCC and 0 for liver dieseases. Since this type of binary variables is non-linear, radial basis function was applied as the kernel function.
In the training group, 835 samples were HCC in 700 cases, while 135 cases of patients were with liver diseases. Among the 360 cases of samples in the testing group, 300 cases had HCC and 60 cases had liver diseases. Analysis results revealed that the accuracy for training was 99.4% and the accuracy of the testing was 85.28% (Table 4 and Supplementary Table 2) . Results of the training and testing groups were completed together to build a classification model.
A diagnostic value of ≥0.95 can be used for the result of determination, while a value <0.95 can be used as a certain reference combined with other methods for determination. As shown in Table 4 , when a diagnosis value ≥0.95 was selected, the precision obtained after training was 99.52%, and the accuracy of the test was 92.18%.
The accurancy of training and testing increased as the accuracy of the test increased.
Verification of the prediction model
After training and testing, a SVM classification prediction model was developed. The model with the remaining 497 HCC samples and 195 liver samples were next validated. Results revealed that prediction accuracy was 91.62% (Table 5) . However, when diagnosis at ≥0.95 was selected, prediction accuracy was improved to 94.98 (Table 5) . Therefore, in the actual diagnosis, it may be better for a doctor set the diagnosis confidence, which would help to improve the diagnostic rate of liver cancer.
However, results of the remaining <0.95 credibility may be confirmed by other methods such as imaging.
ROC curves
The ROC curve is a criterion for measuring the sensitivity and specificity of a marker for HCC. The greater the area under the curve, the higher the sensitivity and specificity, and the more easily it is diagnosed with liver cancer. For conventional diagnosis of the liver cancer factor, ROC curves include single factors such as AFP, γ-glutamyl transferase, platelet, aspartate aminotransferase, and lactate dehydrogenase.
In this study, the overall SVM classifier integrated with 22 markers was considered as a single factor into the ROC curve to compare the maximum area under the curve between them (AUC). In the training group, the AUC of the SVM classifier was 0.784, and the single marker with a maximum AUC was AFP with 0.747 ( Fig. 2A) . In the testing group, the AUV of the SVM classifier was 0.807 and the single marker with a maximum AUC was AFP with 0.727 (Fig. 2B ). These data demonstrate that the AUC of the SVM classifier was significantly greater than the maximum AUC of all other indicators.
Discussion
The molecular pathogenesis of HCC is heterogeneous and very complex (33) .
Although a large number of molecules, signaling pathways and genetic alterations have been found to be associated with HCC (34) (35) (36) , none of these are currently being used for effective screening, early diagnosis, classification, targeted therapy and prognosis (33) . For an individual patient, a tumor is not static, but dynamic, during the process of tumorigenesis and treatment over time (33) . Therefore, the development of methods through the integration of multiple specific markers for early diagnosis is a promising approach. In this study, we obtained 22 algorithm-specific indicators through the relevance analysis of HCC-associated indicators of patients spanning 10 years, and constructed a HCC-SVM classifier based on these 22 indicators to distinguish patients with liver cancer and liver diseases. Our results revealed that the HCC-SVM classifier could well-predict patients with HCC with an accuracy of 91.62% and a higher accuracy rate of 94.98% if a greater than 95% confidence was selected for diagnostic results. Importantly, the AUC of the HCC-SVM classifier ROC curve was greater than the traditional markers of liver cancer AFP. Therefore, our established HCC-SVM classifiers may provide clinicians with an efficient and reliable diagnostic tool to predict liver cancer patients.
In 1999, Vapnik introduced the support vector machine (SVM) for data classification and function approximation (37) . Among all well-known algorithms, SVM is considered to have the most robust and accurate supervised learning algorithm (38) . The SVM optimization process can maximize prediction accuracy and reduce the over-fitting of training data (15) . The basis of SVM is to find the optimal decision boundary by finding the maximum achievable distance between the hyperplane to the maximum the edge (39) . As a result, a larger decision boundary edge has better generalization error than a smaller decision boundary edge, which leads to the generalization ability of an unknown sample. Accordingly, we built our classifier in accordance to the SVM-based method. In addition, we applied radial basis function as the kernel function, because our classification problem is nonlinear In summary, in this study, we first discovered and extracted 22 indicators that are closely associated with liver cancer by correlation analysis. Then, based on these indicators, we established a SVM classifier for the early prediction of liver cancer.
Our validation analysis revealed that the SVM classifier accurately predicted patients with HCC or liver disease. Our study suggests that the SVM classifier would provide as a reliable and effective tool for the diagnosis of early HCC patients.
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